Generic Weight-Loss Drugs Won’t Come for Years
Fernandez cites Biocon, Cipla, Divi’s Labs and Sun Pharma for plans to launch liraglutide in the U.S. and other markets. They ...
Generic drugmaker races to launch versions of blockbuster obesity drugs
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...
Hosted on MSN25d
Mankind Pharma develops oral anti-obesity drug, eyes global breakthrough
Sun Pharmaceutical Industries is developing ... entered the space in 2024 with the launch of Lirafit, a biosimilar of liraglutide. Meanwhile, Biocon has received authorisation to market a generic ...
pharmaphorum1d
Novo Nordisk asks FDA not to allow GLP-1 compounding
The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.
Yahoo Finance1mon
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ...